Lawrence S. Perry

Lawrence S. Perry


Partner, New York

Lawrence S. Perry has extensive experience practicing before the U.S. Patent and Trademark Office, including appeals, interferences, reexaminations, reissues and all phases of patent prosecution in biotechnical, chemical, pharmaceutical, plant genetics, magneto-optical, metallurgical and mechanical technologies. Mr. Perry has extensive opinion work concerning noninfringement, invalidity and freedom to practice in these and other fields.

Case Highlight

Pfizer Inc. v. Teva Pharmaceuticals USA, Inc.
(D. Del. 2012)( 2014)

Obtained U.S. Patent No. 6,197,819 for gamma amino butyric acid analogs and optical isomers (on behalf of Kohn & Associates for Northwestern University), licensed to Pfizer Inc. and Eisai Pharmaceuticals covering Lyrica, with $5.2B global 2014 sales. Validity and infringement confirmed on appeal.

Representative Matters
Notable Prosecution
  • U.S. Patent No. 6,197,819 for gamma amino butyric acid analogs and optical isomers (on behalf of Kohn & Associates for Northwestern University), licensed to Pfizer Inc. and Eisai Pharmaceuticals covering Lyrica, with $5.2B global 2014 sales. Validity and infringement confirmed (Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2012)) and affirmed on appeal (Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2014)).
Interferences
  • Interference No. 102,090 involving circuit for driving multi element display devices.
  • Interference No. 102,091 involving method of maintaining display state in liquid crystal devices.
  • Interference No. 102,092 involving ferroelectric liquid crystal optical displays.
  • Interference No. 102,323 involving method of addressing liquid crystal displays.
  • Interference No. 102,393 involving DNA encoding GM-CSF.
  • Interference No. 103,046 involving method of producing misoprostol.
  • Interference No. 103,424 involving bone morphogenic proteins.
  • Interference No. 104,539 involving photocurable cyanoacrylate compositions.
Reissues
  • Application No. 14/329,255 for process for producing amino acid.
  • Application No. 14/517,148 for antibodies to human IL-1β.
  • Application No. R8/520,642 for porphyrins.
Reexaminations
  • Application No. 90/001,306 for LED with epitaxial wafer.
  • Application No. 90/002,675 for optimized double-press sinter powder metallurgy method.
  • Application No. 90/012,707 for methods of improving display uniformity of organic LED by calibrating individual pixel.
Appeals (USPTO)
  • US Application No. 07/474,648 for producing L-threonine and L-glutamic acid using Corynebacterium or Brevibacterium containing E. coli THR operon or phosphoenolpyruvic acid decarboxylase genes.
  • US Application No. 07/846,776 for cyclic nucleotide phosphodiesterase inhibitors.
  • US Application No. 08/579,731 for optically active 2R,4S benzothiepin isomer.
  • US Application No. 10/271,710 for preserving process sensitive ingredients in energy food product.
  • US Application No. 10/940,026 for producing complex carbohydrate using Corynebacterium culture and nucleotide triphosphate.
  • US Application No. 11/815,225 for determining cholesterol in remnant-like particles.
  • US Application No. 12/700,367 for laser handpiece with fiber optic insert and control unit.
  • US Application No. 13/032,127 for producing fermentation product from sugar hydrolysate.